About this item:

286 Views | 151 Downloads

Author Notes:

Raymond F. Schinazi Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Veterans Affairs Medical Center, Decatur, GA 30033, USA rschina@emory.edu

Emory received no funding from RFS Pharma, LLC to perform this work and vice versa.


Research Funding:

This work was supported in part by NIH grant 5P30-AI-50409 (CFAR), 5R01-AI-071846 and by the Department of Veterans Affairs. Dr. Schinazi is the founder and a major shareholder of RFS Pharma, LLC.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Physical Sciences
  • Chemistry, Medicinal
  • Chemistry, Organic
  • Pharmacology & Pharmacy
  • Chemistry
  • NS5A
  • Antiviral
  • HCV

Synthesis and evaluation of novel potent HCV NS5A inhibitors

Show all authors Show less authors


Journal Title:

Bioorganic and Medicinal Chemistry Letters


Volume 22, Number 14


, Pages 4864-4868

Type of Work:

Article | Post-print: After Peer Review


Judicious modifications to the structure of the previously reported HCV NS5A inhibitor 1, resulted in more potent anti-HCV compounds with similar and in some cases improved toxicity profiles. The synthesis of 19 new NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. For the most potent compounds chemical stability, stability in liver microsomes and inhibition of relevant CYP450 enzymes is also presented.

Copyright information:

© 2012 Elsevier Ltd. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote